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T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
JEM © The Rockefeller University Press  $15.00
Vol. 204, No. 4,  April 16, 2007  747–758  www.jem.org/cgi/doi/10.1084/jem.20062024
747
Although Ig heavy (H) chains of the classes α, ε, 
and γ carry evolutionarily conserved cytoplas-
mic tails of 14–28 amino acids, such structures 
are essentially lacking in μ and δ chains (1–3). 
As the latter are expressed in developing and 
mature naive B cells, the signaling function of 
the B cell receptor (BCR) on those cells is 
thought to rely entirely on the cytoplasmic tails 
of the BCR-associated Igα/β heterodimer. 
However, in the generation of B cell memory, 
most of the antigen-activated B cells participat-
ing in the response switch to the expression of 
other antibody isotypes, and the BCRs on these 
cells acquire the cytoplasmic tail of the newly 
expressed IgH chain as an additional signaling 
module. Although the distinct transmembrane 
domains of the newly expressed IgH chains 
may also contribute to signaling, the functional 
importance of the γ1 and ε cytoplasmic tails 
became apparent in experiments in which the 
gene segments encoding these structures, re-
spectively, were deleted in the mouse germ line, 
and a profound defi  ciency in the development 
of IgG1- or IgE-expressing memory B cells was 
observed (4, 5). These results were complemented 
and extended by a study in which transgenic 
expression of γ1 or μ/γ hybrid chains confer-
ring a particular antigenic specifi  city in combi-
nation with a transgenic κ light chain led to 
an enhanced generation of memory and plasma 
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We describe a mouse strain in which B cell development relies either on the expression of 
membrane-bound immunoglobulin (Ig) 𝗄1 or 𝗍 heavy chains. Progenitor cells expressing 
𝗄1 chains from the beginning generate a peripheral B cell compartment of normal size with 
all subsets, but a partial block is seen at the pro– to pre–B cell transition. Accordingly, 
𝗄1-driven B cell development is disfavored in competition with developing B cells expressing 
a wild-type (WT) IgH locus. However, the mutant B cells display a long half-life and accu-
mulate in the mature B cell compartment, and even though partial truncation of the Ig𝗂 
cytoplasmic tail compromises their development, it does not affect their maintenance, as it 
does in WT cells. IgG1-expressing B cells showed an enhanced Ca2+ response upon B cell 
receptor cross-linking, which was not due to a lack of inhibition by CD22. The enhanced 
Ca2+ response was also observed in mature B cells that had been switched from IgM to 
IgG1 expression in vivo. Collectively, these results suggest that the 𝗄1 chain can exert a 
unique signaling function that can partially replace that of the Ig𝗂/𝗃 heterodimer in B cell 
maintenance and may contribute to memory B cell physiology.
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cell progeny upon antigenic challenge because of reduced cel-
lular attrition (6). The molecular basis of these eff  ects has not 
been elucidated, except by a provocative study suggesting that 
the γ2a cytoplasmic tail enhances BCR signaling by prevent-
ing immunoreceptor tyrosine–based inhibition motif pho-
phorylation of the inhibitory CD22 coreceptor (7).
The conspicuous absence of cytoplasmic tails in μ and δ 
chains could refl  ect peculiar signaling requirements in pre–B 
and immature B cells, predicting that expression of IgH chains 
with cytoplasmic tails would compromise B cell develop-
ment. Indeed, although δ chains alone can effi   ciently mediate 
B cell development (8, 9), transgenic expression of γ chains of 
various classes often seemed to disturb normal development 
(10–15), sometimes promoting the generation of cells coex-
pressing endogenous μ and δ chains (16–20). However, the 
physiological signifi  cance of these experiments remained un-
certain given the variations in transgene copy number and, 
consequently, expression levels inherent in the experimental 
approach. In this paper, we address this question, as well as 
that of the physiological role of γ1 chain–containing BCRs in 
general, in a new experimental setting by replacing the con-
stant region (C) gene cluster in the IgH locus (CH) with a 
loxP-fl  anked simplifi  ed locus containing a Cμ and a Cγ1 
gene segment in opposite orientation in mouse embryonic 
stem (ES) cells, allowing the derivation of mutant strains that 
exclusively express either membrane-bound IgM or IgG1 
in the B cell lineage. It is also possible in these mice to switch 
B cells in the mutant animals from IgM to IgG1 expression, 
or vice versa, in a Cre recombinase–dependent manner.
RESULTS
Construction of a mutant IgH locus from which either 
IgM or IgG1 can be expressed exclusively in a Cre 
recombinase–dependent manner
Starting from ES cells in which the Cδ gene segment re-
placed that of Cμ (9), we constructed an IgH locus whose C 
gene cluster was modifi  ed to contain only the Cμ and Cγ1 
gene segments (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20062024/DC1). These gene segments 
were organized in opposite orientations. The new minilocus, 
which was successfully transmitted into the germ line, was 
fl  anked by loxP sites in opposite orientations, such that Cre-
mediated recombination would either switch B cells in vivo 
from IgM to IgG1 expression (or vice versa) or, when in-
duced in the germ line, generate strains of mice exclusively 
expressing either IgM or IgG1 in the B cell lineage. As our 
original intention was to compare IgM- and IgG-mediated 
antigen presentation by B cells, we deleted the polyA sites 
controlling the production of the secreted forms of the μ and 
γ1 chains, respectively. Depending on the CH gene segment 
in the upstream position, the mutant IgH loci were desig-
nated IgHμγ1 or IgHγ1μ. As expected, homozygous IgHμγ1 
mice produced a B cell compartment consisting exclusively 
of B cells expressing the membrane form of IgM, with no 
IgM being detectable in the blood (unpublished data). In con-
trast, homozygous IgHγ1μ mice exclusively produced IgG1-
expressing B cells, as further described below. However, contrary 
to our expectation, large amounts of IgG1 were detectable in 
the blood of these animals, presumably because of the usage of 
Table I.  B cell populations in the BM
Percentage of all BM cells
Genotype No.
Pro-B 
(A–C)
Pre-B 
(D)
Immature 
(E)
Recirculating 
(F)
IgH+/+ Igα+/+ n = 6 2.8 ± 0.9 14.8 ± 6.3 7.8 ± 1.5 3.3 ± 0.5
IgHγ1μ/γ1μ Igα+/+ n = 6 6.4 ± 2 8.4 ± 5.2 5.1 ± 3.9 4.6 ± 1.9
IgHγ1μ/γ1μ; 
Igα∆c1/∆c1 n = 54  ± 2.3  5.3 ± 2.1  0.83 ± 0.48 0.61 ± 0.37
IgH+/+ Igα∆c1/∆c1 n = 5  6.1 ± 3.6  1.1 ± 0.7 0.59 ± 0.4 0.07 ± 0.06
Values represent the mean ± SD.
Table II.  B cell populations in the spleen
Genotype No.
T cells 
(×106)
B cells 
(×106)
Transitional 
AA4.1+ cells 
(% of B cells)
T1 cells 
(% of 
AA4.1+ cells)
B1 cells 
(% of B 
cells)
B1 cells 
(×106)
MZ cells 
(% of B 
cells)
𝗌1+ cells 
(% of B 
cells)
IgH+/+ Igα+/+  n = 7-10 24.7 ± 9  29.1 ± 7.6  18.6 ± 3.1 55.4 ± 6.2 3.03 ± 0.25 0.97 ± 0.28 7.2 ± 1.2  4 ± 0.8
IgHγ1μ/γ1μ Igα+/+  n = 7-10  28.7 ± 6.6  33.1 ± 13.1 15.5 ± 10  38 ± 4.8 0.96 ± 0.27 0.26 ± 0.11 15 ± 3.5 9.7 ± 0.8
IgHγ1μ/γ1μ; 
Igα∆c1/∆c1  n = 4-8  20.5 ± 6.8 3.7 ± 2 6.6 ± 2.3 58.2 ± 7.8 12.4 ± 3.8 0.37 ± 0.19 7.1 ± 2.4 12.8 ± 2.3
IgH+/+ Igα∆c1/∆c1  n = 4  11.7 ± 2.6 0.3 ± 0.3 ND ND ND ND ND ND
Values represent the mean ± SD.JEM VOL. 204, April 16, 2007  749
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Figure 1.  The 𝗄1 H chain supports B cell development in IgH𝗄1𝗍/𝗄1𝗍 
mice. (A) Genomic structure of the IgHγ1μ locus. To generate the IgHγ1μ 
allele, all CH regions of the IgH locus were replaced by the Cγ1 region, 
followed by the Cμ region in opposite transcriptional orientation, fl  anked 
by inverted loxP sites (triangles). Inversion of the loxP-fl  anked region by 
Cre recombinase generates B cells that exclusively express γ1 (IgHγ1μ) or 
μ (IgHμγ1; not depicted). (B) Flow cytometric analysis of splenocytes from 
IgHγ1μ/γ1μ mice. Expression of membrane IgG1 and IgM by CD19+ B cells 
is shown (top). Splenocytes were stained for CD5 and CD19 expression to 
estimate the ratio between T cells and B cells (second panel from the top). 
The ratio of κ/λ light chain usage in splenic CD19+ B cells is shown (third 
panel from the top). The ratio of MZ B cells (CD19+CD21brightCD23−) and 
follicular B cells (CD19+CD21+CD23bright) is shown (fourth panel from the 
top). Transitional B cell fractions were determined by AA4.1 and CD23 
expression levels (gated on B220+ cells; bottom). Numbers represent the 
percentage of cells within the designated gates. (C) In the two top panels, 
B cell development in the BM of IgHγ1μ/γ1μ mice. B220+ B lymphocytes 
are displayed and gated based on expression levels of surface Ig, 
B220, and the maturation marker AA4.1 to determine the immature 
(B220loIg+AA4.1+; fraction E) and mature (B220hiIg+AA4.1−; fraction F) 
fractions (reference 38). The three bottom panels show the distribution of 
pro–B cell (CD43+CD25−; fractions A–C) versus pre–B cell (CD43−CD25+; 
fraction D) populations within B220+Ig−-gated BM cells. Numbers repre-
sent the percentage of cells within the designated gates. (D) Flow cyto-
metric analysis of peritoneal cells in IgHγ1μ/γ1μ mice. (top) Dot plots 
show the percentages of cells within the lymphocyte gate: T cells 
(CD5highCD19−), B-1a cells (CD19highCD5+), B-1b cells (CD19highCD5low), 
and B-2 cells (CD19lwoCD5low). (bottom) The fraction of CD43+CD19hi cells 
within the CD19+ peritoneal B lymphocytes. (E) IgM and IgG1 titers in 
the sera of IgHγ1μ/γ1μ mice. Ig levels were determined by ELISA. Each dot 
represents values obtained from an individual mouse.750  UNIQUE PROPERTIES OF IGG1 B CELL RECEPTORS | Waisman et al.
an alternative polyA site (Fig. 1 E). B cell development and 
maintenance in this latter mouse strain is the subject of this study.
𝗄1 chains mediate the generation of mature B cells of all subsets
The IgHγ1μ locus is schematically depicted in Fig. 1 A, and 
the populations of B lineage cells in the spleen, BM, and 
peritoneal cavity of homozygous IgHγ1μ mice are depicted 
in Fig. 1 (B–D). A survey of the composition of the various 
B cell compartments in mutant and control animals is given 
in Tables I–III. In the spleens of adult mutant mice, transi-
tional, mature B2, and marginal zone (MZ) B cells could 
be detected on the basis of expression of typical surface mark-
ers, and all B cells expressed IgG1 instead of IgM on the 
  surface. In comparison to the controls, the absolute numbers 
of splenic B cells were normal, but we found a reduction in 
the fractions of transitional, in particular T1, cells and a two- 
to threefold increase in the fraction of MZ B cells (Fig. 1 B 
and Table II). These deviations from the normal situation in-
dicated an impairment of B cell development in the mutant 
animals that became more apparent when B cell development 
in the BM was analyzed by fl  ow cytometry. Staining of the 
cells for B220, c-Kit, CD43, and CD25 revealed a partial 
block at the pro– to pre–B cell transition (Fig. 1 C and Table I). 
Accordingly, although the total cell numbers in the BM of 
IgHγ1μ/γ1μ and WT mice were comparable (11.9 ± 1.7 and 
11.4 ± 1.6 million cells per femur, respectively), the numbers 
of immature B cells in the BM and the spleen, identifi  ed by 
low levels of B220 and high levels of AA4.1, respectively, were 
also somewhat reduced in the mutant animals in comparison 
with the controls (Fig. 1, B and C; and Tables I and II).
Figure 2.  IgG1+ B cells are underrepresented in heterozygous 
IgH𝗄1𝗍/+ mice because of impaired early B cell development rather 
than a reduced life span. (A) IgM+ and IgG1+ fractions of CD19+ B cells 
from spleen, inguinal lymph nodes, and the peritoneal cavity. (right) Dot 
plots represent mice that were treated for 30 d with an IL-7 receptor 
antibody to block the infl  ux of newly generated B cells from the BM. Con-
trols were injected with PBS. The blocking of B cell development in mice 
treated with IL-7 receptor antibody was confi  rmed by fl  ow cytometric 
analysis of the BM cells (not depicted). Numbers represent the percentage 
(mean ± SD) calculated from two experiments with a total of eight mice. 
(B) Life spans of B cells in IgHγ1μ/γ1μ and IgHγ1μ/γ1μ Igα∆c1/∆c1 mice. After 
a labeling period of 1 mo, BrdU incorporation in mature peripheral blood 
B lymphocytes (CD19+CD21+) was measured at the indicated time points 
(day 0 = beginning of chase period). Each symbol represents an indi-
vidual mouse, and the horizontal lines represent the mean. Calculated 
decay curves and half-lives are shown.
Table III.  B cell populations in the peritoneal cavity
B cells B1a B1b B2
Genotype No. % of all cells % of B cells
IgH+/+ Igα+/+ n = 6 72 ± 9  29 ± 13.5 36.8 ± 7  33.8 ± 9.8
IgHγ1μ/γ1μ Igα+/+ n = 6 74 ± 8 6.5 ± 4.6 32.7 ± 7  60.6 ± 8.9
IgHγ1μ/γ1μ; 
Igα∆c1/∆c1 n = 5 12 ± 6 37.9 ± 16.4 50.9 ± 14.8 10.9 ± 5
IgH+/+ Igα∆c1/∆c1 n = 33  ± 1 9.5 ± 5.3 45.6 ± 19.2  44.8 ± 13.9
Values represent the mean ± SD.JEM VOL. 204, April 16, 2007  751
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In the peritoneal cavity, both B1 and B2 cells were de-
tectable in the mutants, but the fraction of B1a 
(CD5+CD43+CD19high) was substantially reduced compared 
with the controls (Fig. 1 D).
We conclude that expression of γ1 instead of μ chains is 
compatible with the development of B cells of all subsets, but 
that the development of B1 and B2 cells is compromised.
B cells expressing Ig𝗄1 chains compete poorly with their 
IgM-expressing counterparts in development but 
mature into long-lived, B cell–activating factor 
(BAFF)–dependent cells that respond to BCR 
and Toll-like receptor (TLR) stimulation
Heterozygous IgHγ1μ mice allowed us to study the develop-
ment of γ1 and μ/δ chain–expressing B cells in competition. 
As expected from the compromised development of IgG1-
expressing cells (Fig. 1 C), the peripheral B cell compartment 
was dominated in this situation by IgM-expressing B cells 
by a factor of 6 in the spleen and lymph nodes and >10 in 
the peritoneal cavity (Fig. 2 A, left). Both IgM- and IgG1-
expressing cells were long lived, but the IgG1-expressing cells 
persisted as well as and perhaps even slightly better than their 
IgM-expressing counterparts over 30 d of treatment with 
anti–IL-7 antibody, which blocks B cell generation in the BM 
(Fig. 2 A, right) (21). The longevity of the cells was also deter-
mined in IgHγ1μ homozygous mice by measuring the decay of 
cells having incorporated BrdU, after a feeding period of 1 mo, 
over time (Fig. 2 B). Strikingly, the apparent half-life of the 
mutant cells, averaged over the population of CD19+CD21+ 
B cells in the blood, was longer than that of WT cells by a fac-
tor of 1.5. This diff  erence does not necessarily indicate an in-
trinsic property of these cells distinguishing them from their 
IgM- and IgD-expressing counterparts but could simply re-
fl  ect the diminished output of B cells from the BM in the 
mutant animals. Nevertheless, the mutant cells were clearly 
long-lived, and this explains how IgHγ1μ mice can generate a 
peripheral B cell compartment similar in size to that of WT 
mice despite a defect in B cell generation. It may also explain 
why the apparent counterselection of the IgG1- expressing 
cells is stronger at the level of immature and transitional T1 
cells as compared with mature B cells (Table IV).
Figure 3.  BAFF-R dependence of IgG1+ B cells. (A) BAFF-R expres-
sion levels in CD19+ splenic B cells. (B) Flow cytometric analysis of splenic 
B cells from IgHγ1μ/+ BAFF-R−/− mice. IgG1+ B cells depend on BAFF-R 
for maintenance. (top) B220+ B cells from IgHγ1μ/+ BAFF-R−/− mice and 
IgHγ1μ/+ BAFF-R−/+ controls. (bottom) The IgM+ and IgG1+ B cell frac-
tions from the top panel are further analyzed for their mature (AA4.1−) 
versus immature (AA4.1+) composition. Numbers represent the percent-
age of cells within the designated gates.
Table IV.   Survival advantage of IgG1+ cells over IgM+ competitor B cells
IgG1+/IgM+ ratio
BM Spleen
Genotype No. Immature
Mature/ 
recirculating T1 T2/T3
All 
transitional Mature
AA4.1+ 
B220+
AA4.1− 
B220+
AA4.1+CD23− 
CD19+
AA4.1+CD23+ 
CD19+
AA4.1+ 
CD19+
AA4.1− 
CD19+
IgHγ1μ/+ Igα∆c/+ n = 5 0.06 ± 0.01 0.16 ± 0.02 0.058 ± 0.012 0.106 ± 0.007 0.08 ± 0.01  0.16 ± 0.02
IgHγ1μ/+ Igα∆c1/∆c1 n = 5 0.83 ± 0.22 2.24 ± 0.71 ND ND 2.09 ± 0.29 2.68 ± 0.3
In heterozygous IgHγ1μ/+ Igα∆c+/+ and IgHγ1μ/+ Igα∆c1/∆c1 mice, the IgG1+/IgM+ B cell ratio increases with the maturational status. Note the strong increase of the fraction of 
IgG1+ B cell presence within the mature compartment. BM and splenic cells were surface stained for IgG1/IgM, AA4.1, CD23, and a B cell–specifi  c marker (B220 or CD19) and 
analyzed by fl  ow cytometry.752  UNIQUE PROPERTIES OF IGG1 B CELL RECEPTORS | Waisman et al.
Figure 4.  IgG1+ B cells show enhanced proliferative and Ca2+ 
  responses, which are not caused by a lack of CD22 inhibition, upon 
BCR cross-linking. (A) Proliferative responses of IgHγ1μ/γ1μ B cells. Spleen 
cells from WT and IgHγ1μ/γ1μ mice were labeled with CFSE, stimulated with 
the indicated mitogenes, and analyzed by fl  ow cytometry 4 d later. Histo-
grams display CFSE fl  uorescence of B220+ B cells. A representative analy-
sis of four independent experiments is shown. (B) Immunoblotting for 
BCR-induced JNK, ERK, Akt, and IκBα phosphorylation. Splenic follicular 
B cells (B220+CD21+CD23bright) from WT and IgHγ1μ/γ1μ mice were sorted 
with a FACSVantage and stimulated with 20 μg/ml anti-kappa for the 
indicated times. Whole-cell lysates were separated by SDS-PAGE and 
immunoblotted with the indicated antibodies. β-actin levels are shown as 
a loading control. (C) Ca2+ responses of IgHγ1μ B cells upon BCR cross-
linking in the absence and presence of CD22. Indo-1–loaded splenocytes 
were stimulated with 1 or 0.4 μg/ml anti-kappa at the time points indi-
cated by the arrows. Histograms show Ca2+ B cell responses (CD5− Mac-1−), 
displayed as the means of the 405/485-nm emission ratio over time. 
(D) Immunoprecipitation of CD22 and the BCR complex from IgHγ1μ/γ1μ 
splenic B cells. Splenic B cells from WT and IgHγ1μ/γ1μ mice were stimu-
lated with 10 μg/ml anti-kappa for the indicated times, and CD22 was 
immunoprecipitated from the lysates. Coprecipitated proteins were de-
tected with antiphosphotyrosine (anti–p-Tyr), anti–SHP-1, and anti-CD22. 
Numbers indicate the fold increase in phosphorylation of CD22 and the 
amount of SHP-1 precipitated compared with unstimulated WT samples, 
normalized to total CD22. Additionally, fi  ve experiments were analyzed, 
and means and SDs were calculated. The results were in the same order as 
in the fi  gure: anti–p-Tyr (control), 1, 2.3 ± 0.1, 1.7 ± 0.5, and 0.8 ± 0.1; 
IgHγ1μ/γ1μ mice, 0.8 ± 0.1, 2.2 ± 0.1, 1.7 ± 0.3, and 1.2 ± 0.2; anti–SHP-1 JEM VOL. 204, April 16, 2007  753
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Like mature IgM- and IgD-expressing B cells, the ma-
ture IgG1-expressing B cells in heterozygous IgHγ1μ mice 
were dependent on BAFF–BAFF-R interaction, as shown 
by the loss of mature (B220+AA4.1−), but not transitional 
(B220+AA4.1+), splenic B cells in IgHγ1μ/γ1μ and WT mice 
on a BAFF-R–defi  cient background (Fig. 3 B). Interestingly, 
the IgG1-expressing B cells in homozygous IgHγ1μ mice ex-
pressed lower levels of BAFF-R than WT B cells (Fig. 3 A), 
supporting the notion that there is a link between BCR sig-
naling and BAFF-R expression (22).
The B cells of the mutant animals responded vigor-
ously to mitogenic stimuli addressing TLRs or the BCR by 
proliferation. Although the proliferative responses of the IgG1-
expressing B cells through TLRs and CD40 ligation were not 
notably diff  erent from those of control B cells, we observed a 
distinctly enhanced fraction of highly proliferating mutant cells 
upon BCR cross-linking (Fig. 4 A). These diff  erences were more 
pronounced when low doses (1–10 μg/ml) of the cross-linking 
anti-kappa antibody were used (Fig. 4 A and not depicted).
B cells of IgH𝗄1𝗍 mice show enhanced BCR-triggered 
Ca2+ responses, which are not caused by uncoupling 
from CD22-mediated inhibition
Although IgG1-expressing cells responded to BCR cross-
linking by normal or dampened—rather than enhanced—
total tyrosine phosphorylation and c-Jun N-terminal kinase 
(JNK), extracellular signal–related kinase (ERK), Akt, nu-
clear factor of activated T cells 2, and IκBα phosphorylation 
(Fig. 4 B and not depicted), a clear diff  erence between IgG1-
expressing and WT cells in the stimulation experiments was 
enhanced Ca2+ mobilization upon BCR cross-linking (Fig. 
4 C and Fig. S2, available at http://www.jem.org/cgi/ 
content/full/jem.20062024/DC1). This enhanced response was 
also seen in mature B cells that had been acutely switched 
from IgM to IgG1 expression in vivo through induced Cre-
mediated recombination (Fig. 4 E). The enhanced Ca2+ re-
sponse in IgG1-expressing B cells is not caused by increased 
levels of BCR expression (Fig. S3). To address whether it re-
sults from an impairment of CD22 inhibition (7), IgHγ1μ/γ1μ 
mice were crossed to CD22 knockout animals, and anti-
kappa–induced Ca2+ mobilization was measured in B cells 
from the compound mutants. Anti-kappa–induced Ca2+ sig-
naling was strongly increased in IgHγ1μ/γ1μ CD22−/− B cells 
compared with the response of IgHγ1μ/γ1μ B cells, despite the 
fact that the latter is already considerably stronger than that of 
WT cells (Fig. 4 C). This increase in the Ca2+ response was 
found over a wide range of anti-kappa antibody concentra-
tions (from 0.4 to 15 μg/ml; unpublished data). Thus, CD22 
defi  ciency causes an increase of Ca2+ fl   ux, irrespective of 
whether the cells express an IgM and IgD or an IgG1 BCR.
We also compared tyrosine phosphorylation of CD22 
and Src homology domain 2–containing protein tyrosine 
phosphatase (SHP-1) recruitment between control (IgM/
IgD-expressing) and IgG1-expressing B cells after BCR 
  stimulation. Anti-kappa–stimulated splenic B cells were analyzed 
by immunoprecipitation of CD22, and equal tyrosine phos-
phorylation of CD22 was found in splenic B cells of control 
IgHγ1μ/γ1μ mice. We also could not detect any quantitative 
diff  erences in SHP-1 recruitment to CD22 in the two types 
of cells when several experiments were quantifi  ed (Fig. 4 D). 
This is in contrast to the published results from cell line stud-
ies in which IgG2a B cells did not show any CD22 tyro-
sine phosphorylation and SHP-1 recruitment after stimulation 
with antigen (7). In that report, it was also postulated that 
there may be diminished association of CD22 to BCRs of the 
IgG2a isotype. Therefore, we performed immunoprecipita-
tion with Igκ-specifi  c antibodies and looked for the amount 
of coprecipitated CD22. We found that the same amount of 
CD22 protein could be coprecipitated from unstimulated 
and stimulated B cells of control and IgHγ1μ/γ1μ mice and that 
the coprecipitated CD22 exhibited comparable tyrosine 
phosphorylation (Fig. 4 D). We conclude that in IgG1-
expressing B cells of IgHγ1μ/γ1μ mice, normal activation of 
CD22-dependent pathways takes place. The higher Ca2+ re-
sponse of IgHγ1μ/γ1μ mice can also not be attributed to 
changed B cell subpopulations in their spleens, because a simi-
larly increased Ca2+ response was detected in lymph-node B 
cells (Fig. S2).
We also addressed the question of whether CD22 defi  -
ciency aff  ects B cell subsets in IgHγ1μ/γ1μ mice. In the BM, 
a similar composition of B cells was found in IgHγ1μ/γ1μ 
CD22−/− and IgHγ1μ/γ1μ mice. Although CD22−/− mice 
show a characteristic reduction of mature recirculating B cells 
(B220hi IgM+), a reduction of B220hi IgG1+ cells was not 
seen in IgHγ1μ/γ1μ mice on a CD22-defi  cient background 
(Fig. S4 A, available at http://www.jem.org/cgi/content/
full/jem.20062024/DC1). In the spleen, a considerably higher 
number of IgG1+ B cells was present in heterozygous IgHγ1μ/+, 
(control), 1, 1.5 ± 0.8, 1.2 ± 0.8, and 1 ± 0; and IgHγ1μ/γ1μ mice, 1 ± 0.4, 
1.4 ± 0.7, 1.2 ± 0.4, and 0.9 ± 0.3. To analyze CD22 association with the 
BCR, Igκ was immunoprecipitated from whole-cell lysates of splenic 
B cells. Coprecipitation of phosphorylated and total CD22 was determined 
by immunoblotting. Numbers at the bottom of each panel indicate fold 
increases of coprecipitated phosphorylated CD22 or coprecipitated total 
CD22 compared with unstimulated WT samples, normalized to anti-kappa 
signal. Means and SDs were calculated from three experiments in the 
same order as in the fi  gure: anti–p-Tyr (control), 1, 1.3 ± 0.3, and 1.4 ± 0.5; 
IgHγ1μ/ γ1μ mice, 10 ± 0.2, 1.3 ± 0.5, and 1.7 ± 1; total CD22 (control), 
1, 1.1 ± 0.1, and 1 ± 0.1; and IgHγ1μ/γ1μ mice, 0.9 ± 0.1, 1.1 ± 0.2, and 
1.1 ± 0.1. (E) Ca2+ mobilization upon BCR cross-linking in splenic B cells 
carrying the IgHμγ1 allele, which were acutely switched to IgG1 orientation. 
Purified splenic B cells from IgHμγ1/JHT Cre-ERT2 mice treated with 
tamoxifen were stained with Cy5-conjugated anti-IgM Fab fragments and 
loaded with Fluo-3 and Fura Red. Loaded cells were gated for IgM+ or 
IgM− (switched) and stimulated with the indicated doses of anti-kappa 
at the time points indicated by the arrows. The relative intracellular Ca2+ 
concentration is displayed as the ratio between Fluo-3 and Fura Red 
mean fl  uorescence intensity over time.754  UNIQUE PROPERTIES OF IGG1 B CELL RECEPTORS | Waisman et al.
CD22-defi  cient mice compared with their CD22-profi  cient 
counterparts (Fig. S4 B). The MZ B cell compartment was 
enlarged in both CD22-profi  cient and -defi  cient IgHγ1μ/γ1μ 
mice, contrasting the reduction of MZ B cells in CD22-defi  -
cient mice carrying WT IgH loci (however, note that diff  er-
ences in genetic backgrounds may play a role in this case; Fig. 
S4 C) (23). Similar to IgHγ1μ/γ1μ mice, IgHγ1μ/γ1μ CD22−/− 
mice had a strongly reduced B1a cell population in the peri-
toneal cavity (Fig. S4 D).
B cell development and maintenance in IgH𝗄1𝗍 mice is less 
dependent on an intact Ig𝗂/𝗃 heterodimer than in WT mice
Normal B cell development is severely compromised in mice 
carrying a mutation in the mb-1 gene that leads to a partial 
Figure 5.  IgH𝗄1𝗍 B cells are less dependent on the Ig𝗂 cytoplasmic 
domain than WT B cells. Flow cytometric analysis of compound mutant 
animals with the IgHγ1μ and Igα∆c1 alleles. (A) BM B220+ B cell subsets 
from mice with the indicated genotypes to determine the fractions of 
recirculating (B220highIg+; fraction F) and immature (B220lowIg+; fraction E) 
B cells. (bottom) B220+Ig− BM cells were gated based on CD43 expression 
of pro– (CD43+; fractions A–C) and pre–B cells (CD43−; fraction D). 
(B) Splenic lymphocytes were stained for CD19 and CD22 expression. 
Note that CD22 expression levels are comparable for B cells from WT and 
IgHγ1μ/γ1μ mice. (C) Splenic (top) and peritoneal (middle) CD19+ B cells 
were analyzed for CD5 surface expression. (bottom) The size and CD43 
expression levels of peritoneal CD19+ cells. (D, top) CD19+ splenic B cells 
from heterozygous IgHγ1μ mice with the Igα mutation were analyzed for 
the expression of IgM and IgG1. (bottom) Relative surface expression 
levels (percentages) of IgG1 and IgM for CD19+ splenic B cells. Expression 
levels in the context of WT Igα are set to 100. The histogram shows a 
representative example. Numbers in A–D indicate the percentage of cells 
within the designated gates. (E) Spleen sections stained by immunohisto-
chemistry to identify B cells (blue) and T cells (red). Bar, 1 mm.JEM VOL. 204, April 16, 2007  755
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ablation of the cytoplasmic tail of the Igα signal trans-
ducer. Such animals generate <1% of normal mature B cell 
numbers, and these cells do not accumulate, presumably be-
cause of a shortened life span (24, 25). We wondered 
whether expression of the γ1 chain in the BCR would 
rescue B cell development and maintenance in mice carrying 
a truncated Igα chain. Therefore, double-mutant mice ho-
mozygous for the Igα truncation mutation (Igα∆c1) and 
homo- or heterozygous for IgHγ1μ were generated. The Igα 
truncation clearly impeded B cell development in the IgHγ1μ 
mice, as refl  ected by reduced fractions of immature and ma-
ture B cells in the BM and spleen (Fig. 5, A and B; and Tables 
I and II). Like in WT mice, an Igα-null mutation led to a 
complete block of B cell development in IgHγ1μ/γ1μ mice 
(Fig. S5, available at http://www.jem.org/cgi/content/full/
jem.20062024/DC1). However, in comparison to mice car-
rying the Igα truncation on a WT background, Igα∆c1/ ∆c1 
IgHγ1μ/γ1μ double mutants displayed a 10-fold larger fraction 
of mature B cells in the spleen (Fig. 5 B and Table II), which 
were partly organized into small B cell follicles (Fig. 5 E) and 
had a life span indistinguishable from that of their Igα-suffi   -
cient counterparts (Fig. 2 B). In accord with these results, 
when the Igα mutation was combined with IgHγ1μ/+ hetero-
zygosity, we observed a dramatic preponderance of cells ex-
pressing IgG1 BCRs over those expressing BCRs associated 
with IgM (Fig. 5 D). We conclude that the presence of γ1 
chains in the BCR makes the maintenance, but not the devel-
opment, of the cells independent of the Igα cytoplasmic tail.
Curiously, combining the IgHγ1μ with the Igα∆c1 muta-
tion promoted B1a cell development in both the peritoneal 
cavity and spleen beyond what is seen in IgHγ1μ/γ1μ mice 
(Fig. 5 C and Tables II and III). The fraction of these cells 
was strongly reduced in IgHγ1μ mice, but when the majority 
of the B2 cells were depleted through the Igα mutation, they 
became the dominant fraction in the peritoneal cavity. We 
also noted that the splenic B cells developing in the double-
mutant mice had increased surface levels of IgG1 BCRs, with 
some increase being detectable even in animals heterozygous 
for the Igα truncation (Fig. 5 D). However, the levels of 
BAFF-R on these cells were unaff  ected by the Igα truncation 
(unpublished data).
DISCUSSION
We describe a mouse strain whose IgH locus is engineered 
such that either membrane-bound γ1 or μ chains can be 
produced through Cre-mediated inversion of a loxP-fl  anked 
CH region gene minilocus containing the Cγ1 and Cμ gene 
segments in opposite orientation. This strain can be used ei-
ther for switching B cells from IgM to IgG1 expression, and 
vice versa, through induced Cre recombinase expression or 
to generate strains in which B cell development relies on the 
exclusive usage of membrane-bound μ or γ1 chains, respec-
tively. In this paper, we use this system to study B cell de-
velopment and maintenance in the latter situation. A main 
advantage of the present approach over earlier experiments, 
in which the developmental potential of IgH transgenes 
  encoding H chains of various isotypes was analyzed, is that we 
can study B cell development under conditions in which the 
cells go through VH region diversifi  cation, like in WT mice, 
instead of starting from a prerearranged IgH transgene encod-
ing a single VH region. We have indeed observed that homo-
zygous IgHγ1μ mice produce a highly diverse repertoire of 
IgH chain–variable regions in their mature B cell compart-
ment, indistinguishable in a fi  rst approximation from that of 
WT mice (unpublished data). The present system also avoids 
the serious complications of copy number and position-
dependent variations of transgene expression (15), in that 
IgH expression is controlled by the very same VH promoters 
that are used in normal B cell development.
In homozygous IgHγ1μ mice, all B cells indeed express 
IgG1, and in the blood of the animals we detect IgG1 but no 
IgM antibodies. Although B cells of all subsets are generated 
and the overall size of the peripheral B cell compartment is 
similar to the one for WT mice, B cell development in the 
BM is clearly compromised, with a partial developmental 
block at the pro– to pre–B cell transition. The nature of this 
block, whose elucidation will require the generation and 
analysis of pro–B cell lines from the mutant animals, likely 
lies in the inadequate assembly or signaling capacity of the 
pre-BCR (pBCR) in the mutant animals, given that the 
pBCR plays a crucial role at this very point in development 
(26, 27). Indeed, in pBCR-defi  cient mice, B cell develop-
ment is largely blocked at the pro– to pre–B cell transition, at 
which the cells go through a pBCR-dependent phase of 
rapid proliferation. The developmental block seen in the 
IgHγ1μ animals is clearly much milder, in that not only do 
many more B cells develop in these animals over time but 
also a normal fraction of large, cycling cells is seen in the pre–
B cell compartment (unpublished data), which are lacking in 
pBCR-defi  cient mice (28). We therefore speculate that a γ1 
chain–containing pBCR-like molecular complex is assem-
bled in the animals but is functionally compromised. This 
problem is currently under investigation.
As predicted by this scenario, the mutant cells compete 
poorly in development with their WT counterparts in het-
erozygous IgHγ1μ mice. This eff  ect is more dramatic at the 
level of immature B cells in the BM and transitional T1 B cells 
in the spleen than that of mature splenic B cells. The accumu-
lation of IgG1-expressing mature B cells in these animals 
could be explained by prolonged average life spans for these 
cells as compared with those of WT, IgM-, and IgD-expressing 
cells. At face value, this is indeed independently suggested by 
the BrdU chase data in Fig. 2 B, but one should bear in mind 
that these data could mainly refl  ect the dependence of B cell 
turnover on B cell output from the BM. It is well established 
that the average half-life of B cells is dramatically prolonged 
when B cell generation in the BM is blocked (29).
Homozygous IgHγ1μ/γ1μ mice showed characteristic shifts 
in peripheral B cell populations, with reduced numbers of B1 
cells and higher splenic MZ B cell counts. Interestingly, a 
companion study by Horikawa et al. using transgenic mice 
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MZ B cell population (see Horikawa et. al [30] on p. 759 
of this issue). Although the MZ B cell expansion may be re-
lated to a decreased cellular output from the BM, the B1 cell 
defect is likely caused by improper signaling properties of the 
IgG1 BCR. Our biochemical data from splenic B cells argue 
that these are not based on an uncoupling of the inhibitory 
CD22 receptor from the BCR. The B1 cell defect is likely 
also CD22 independent, because CD22 has been shown not 
to modulate the Ca2+ responses of B1 cells (31).
Mature B cells expressing an IgG1 BCR exhibited en-
hanced Ca2+ mobilization upon BCR cross-linking as com-
pared with WT B cells, irrespective of whether the cells had 
gone through development as γ1-expressing cells or had their 
BCR switched from IgM to IgG1 after maturation. Although 
the biochemical basis of this enhanced signaling capacity of 
the IgG1 BCR remains to be elucidated, it clearly does not 
refl  ect an inability of the inhibitory CD22 receptor to dampen 
the response of the mutant cells, as earlier work on B cell 
lines expressing an IgG2a BCR had indirectly suggested (7). 
This is also born out in the accompanying study by Horikawa 
et al. (30) in which antigen-specifi  c IgG1- and IgM-transgenic 
mice are compared with respect to their BCR responses and 
the role of CD22 inhibition. In the work of Wakabayashi 
et al. (7), an antigen-specifi  c γ2a chain was stably expressed 
in various B cell lines. It is therefore possible that the results 
obtained in that study refl  ect a peculiarity of the particular 
IgH chain used or of the B cell clones selected. In the present 
system, as well as in that of Horikawa et al. (30), mice are 
used that express a diverse repertoire of γ1 chains in the B 
cell compartment in vivo. As γ2a and γ1 chains are very sim-
ilar and no diff  erent functions have as yet been attributed to 
their cytoplasmic tails (32), we speculate that the present re-
sults may refl  ect common signaling properties of IgG BCRs 
in normal physiology.
Although the enhanced Ca2+ response to BCR cross-
linking in B cells expressing IgG1 BCRs may refl  ect  the 
unique signaling properties of the latter, we have so far been 
unable to identify signaling cascades that are selectively acti-
vated through the BCR in IgG1-expressing cells. Indeed, 
phophorylation of known players in BCR signaling like JNK, 
ERK, Akt, nuclear factor of activated T cells 2, and IκBα was 
normal or dampened, rather than enhanced, in these cells 
compared with their IgM- and IgD-expressing counterparts. 
Total tyrosine phosphorylation was also not enhanced in IgG1 
cells. These issues clearly need further investigation, particu-
larly in cells acutely switched from IgM to IgG1 expression.
We did not observe enhanced proliferation of the mu-
tant cells upon TLR ligation in vitro, but upon BCR cross-
linking, the fraction of highly proliferating cells was increased. 
The latter eff  ect is likely not caused by an increased fraction 
of MZ B cells in the mutant mice, because follicular B cells 
proliferate better than MZ B cells upon BCR cross-linking 
(33). Our results are in line with earlier experiments by Martin 
and Goodnow (6) in which B cells expressing a transgenic 
IgG1 of defi  ned antigenic specifi  city were triggered by antigen. 
The mutant cells in the latter study generated strikingly larger 
numbers of progeny cells than antigen- activated cells express-
ing transgenic IgM and IgD because of their enhanced survival. 
In the present experiments, the enhanced in vitro proliferation 
upon BCR cross-linking, as well as the accumulation of IgG1-
expressing cells in the mature B cell compartment in the het-
erozygous mutant animals (i.e., when the cells compete with 
IgM- and IgD-expressing cells), may similarly refl  ect an en-
hanced effi   ciency by which survival signals are delivered to the 
cells via the BCR upon isotype switching, as it typically occurs 
in the generation of memory B cells. It will be interesting to 
see whether we can use the present experimental system to be-
stow enhanced in vivo survival to IgM-expressing cells by 
switching them to IgG1 expression through induced Cre re-
combinase activity and, thus, to assess whether expression of 
the IgG1 BCR as such increases the life span of these cells.
As the BCR acquires a new signaling module in terms of 
the cytoplasmic tail and, perhaps, other parts of the newly 
expressed IgH chain upon isotype switching, it was of inter-
est to ask whether the cytoplasmic tails of the Igα/β het-
erodimer, which mediate signal transduction through IgM 
and IgD BCRs, are required for the maintenance of B cells 
expressing an IgG1 BCR. Indeed, we had previously shown 
that the Igα cytoplasmic tail is required for the survival of 
mature B cells in WT mice (24, 25). We now demonstrate 
that, in contrast to this result, the partial truncation of the Igα 
cytoplasmic tail does not impede the survival of B cells ex-
pressing an IgG1 BCR. The simplest interpretation of this 
fi  nding is that, in accord with the considerations above, the 
γ1 chain, likely through its conserved cytoplasmic tail, in-
deed delivers a survival signal to the cells, and that this signal 
contributes to the longevity of memory B cells expressing 
class-switched BCRs. However, we also note that in the 
compound mutant animals, B cell development is profoundly 
compromised, in that the animals produce only one tenth of 
the normal numbers of B cells. Although this is still roughly 
10 times more cells than in animals carrying a WT IgH locus 
in combination with the Igα truncation (24, 25), we cannot 
exclude that the cells generated in these animals are a selected 
population of B cells that are not representative of the B cell 
population generated in WT mice.
MATERIALS AND METHODS
Mice. Igα∆C1/∆C1, Igα∆Tm/∆Tm, BAFF-R−/−, and CD22−/− mice were de-
scribed previously (24, 34, 35) and kept on C57BL/6 (Igα∆Tm/∆Tm and 
BAFF-R−/−), 129 (CD22−/−), or mixed 129 × C57BL/6 (Igα∆C1/∆C1) ge-
netic backgrounds. Mice were analyzed at the ages of 6–16 wk. The genera-
tion of the IgHμγ1 and IgHγ1μ mouse strains is described in Fig. S1. Both 
strains were generated from BALB/c-derived ES cells and kept on a BALB/c 
background. The sequence of the mutant locus is available from GenBank/
EMBL/DDBJ under accession no. EF495199. Mice were bred and main-
tained under specifi  c pathogen-free conditions. Animal care and experiments 
were conducted according to protocols approved by the Harvard University 
Institutional Animal Care and Use Committee and by the CBR Institute for 
Biomedical Research.
Flow cytometry. Preparations of cell suspensions from lymphoid organs and 
cell-surface stainings were performed as previously described (36). Data were 
acquired on a FACSCalibur (BD Biosciences) and analyzed using CellQuest JEM VOL. 204, April 16, 2007  757
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(BD Biosciences) and FlowJo (TreeStar Inc.) software. Dead cells were la-
beled with propidium iodide or TO-PRO-3 iodide (Invitrogen) and ex-
cluded from the analysis. Monoclonal antibodies R33-24.12 (anti-IgM), 
1.3-5 (anti-IgD), RA3-6B2 (anti-B220), R33-18-10 (anti-Igκ), and 
M5/114 (anti-IAb) were prepared and conjugated in our laboratory. Mono-
clonal antibodies to CD5, CD19, CD21/35, CD22, CD23, CD24, CD25, 
CD43, CD69, CD86, CD95, CD117, Igλ, IgG1, and H2Kb were purchased 
from BD Biosciences. The monoclonal antibody to AA4.1 was purchased 
from eBioscience. AA4.1-PE (anti-C1qRp) was a gift from M.P. Cancro 
(University of Pennsylvania School of Medicine, Philadelphia, PA). Rabbit 
polyclonal antibodies to mouse BAFF-R were generated as previously 
described (34). Ig serum concentrations were determined by ELISA, as 
described previously (36).
BrdU labeling and block of B cell lymphopoiesis. 0.8 mg/ml BrdU 
(Sigma-Aldrich) was given in the drinking water for 31 d. Lymphocytes 
were surface stained for CD19 and CD21, and BrdU incorporation was de-
termined with the BrdU Flow Kit (BD Biosciences).
To block B cell lymphopoiesis in the BM of IgHg1m/+ heterozygous 
mice, 1 mg anti–IL-7R monoclonal antibody (A7R34) was injected i.v. 
every second day.
B cell activation. 2–10 × 106 B cells/ml were incubated with carboxyfl  u-
orescein succinimidyl ester (CFSE; Invitrogen) in RPMI 1640 (Invitrogen) 
containing 5 mM CFSE for 5 min at 37°C. CFSE-labeled cells were cultured 
in 200 μl complete DMEM (Invitrogen) at a concentration of 4 × 106 
cells/ml in 96-well microtiter plates at 37°C in the presence of diff  erent 
mitogenes. Cells were analyzed by fl  ow cytometry. For activation, anti-
RP105 antibody (eBioscience), LPS (Salmonella minnesota Re 595; 
Sigma-Aldrich), IL-4 (PeproTech), anti-CD40 (BD Biosciences), CpG 
(phosphothioate-stabilized CpG-ODN [ T  C  C  A  T  G  A  C  G  T  T  C  C  T  G  A  -
T  G  C  T  ]; TIB MOLBIOL), or anti-IgM F(ab′)2 fragments (Jackson Immuno
Research Laboratories) or anti-kappa (Southern Biotechnology Associates, 
Inc.) were used.
Ca2+ mobilization. Splenocytes were resuspended in RPMI 1640 supple-
mented with 1% FCS (5 × 106 cells/ml) and incubated with 4.5 μM Indo-1 
and 0.003% Pluronic F-127 (Invitrogen) at 37°C for 45 min. Afterward, 
splenocytes were stained on ice with anti–Mac-1–FITC and anti-CD5–PE 
(BD Biosciences), followed by acquisition with a FACSVantage (BD Bio-
sciences) and stimulation with anti-kappa at the concentrations indicated in 
Fig. 4. Data were analyzed using FlowJo software.
Immunoblotting and immunoprecipitation. After red blood lysis, 
splenic B cells were negatively selected using CD43 magnetic beads   (Miltenyi 
Biotec) and stained with B220, CD21, and CD23 antibodies. Follicular 
B cells (B220+, CD21+, CD23bright) were sorted with a FACSVantage and 
resuspended in complete B cell medium at a concentration of 2 × 106 cells/ml. 
After preincubation for 1 h at 37°C, cells were stimulated with 20 μg/ml 
anti-kappa and lysed in RIPA lysis buff  er (40 mM Tris, pH 7.6, 150 mM 
NaCl, 2 mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, 5 μg/ml apro-
tinin, 2 μM pepstatin, 10 μg/ml leupeptin, 1 mM PMSF, 5 mM NaF, 0.5 μM 
okadaic acid, 1 mM Na3VO4). Protein concentrations were determined by 
a Protein Assay Kit (Bio-Rad Laboratories), and 6 μg of protein per lane was 
separated by a 10% SDS-PAGE and transferred to a polyvinylidene difl  uoride 
membrane (Millipore). The membranes were immunoblotted with phospho-
ERK1/2 (T202/Y204), phospho-JNK1/2 (T183/Y185), phospho-Akt 
(S473), phospho-IκBα (S32/36), anti-ERK1/2, anti-JNK1/2, anti-Akt (Cell 
Signaling), anti-IκBα (Santa Cruz Biotechnology, Inc.), and anti–β-actin 
(Sigma-Aldrich) antibodies.
For co-immunoprecepitation experiments, splenic B cells were purifi  ed 
after erythrocyte lysis by a complement lysis of T cells. 107 B cells/ml were 
stimulated with anti-kappa at 37°C for the times indicated in the fi  gures. 
After stimulation, cells were lysed in lysis buff  er (50 mM Tris [Roth], pH 
7.5, 6.6 mM NaCl [Roth], 0.5 mM EDTA [Applichem], 1 μg/ml apro-
tonin [Roche], 5 μg/ml leupeptin [Roche], 1 mM PMSF [Roche], 1 mM 
Na3VO4 [Sigma-Aldrich], 1% Brij-58 [Sigma-Aldrich]) and incubated for 
30 min on ice. The lysates were centrifuged and immunoprecipitated with 
rabbit anti-CD22 (a gift from P. Crocker, University of Dundee, Dundee, 
UK) and protein A–sepharose (GE Healthcare) or anti-kappa antibody and 
protein G–sepharose (GE Healthcare). Immune-complexed coated beads 
were collected after overnight incubation and washed three times with 
ice-cold lysis buff  er. After boiling the beads for 3 min in a reducing sample 
buff  er, supernatants were separated by a 7.5% SDS-PAGE and transferred to 
nitrocellulose membranes (BioTrace NT; Pall). Membranes were incubated 
with primary antibodies 4G10 (Upstate Biotechnology), SHP-1 (Biozol), 
and anti-kappa overnight at 4°C. Secondary antibodies were goat anti–
mouse IgG–horseradish peroxidase (HRP; Jackson ImmunoResearch Labo-
ratories) and goat anti–rabbit IgG-HRP (Santa Cruz Biotechnology, Inc.). 
Membranes were developed with ECL (GE Healthcare). Blots were scanned, 
and band intensities were quantifi  ed using ImageJ software (National Insti-
tutes of Health).
In vivo induction of IgG1 expression and Ca2+ fl  ux measurement in 
switched cells. To induce in vivo inversion of the IgHμγ1 allele with subse-
quent expression of IgG1 instead of IgM in B cells, IgHμγ1/JHT Cre-ERT2 (37) 
mice were fed for 3 d with 1–5 mg tamoxifen (Sigma-Aldrich) per mouse by 
gavage (depending on the weight of the recipients). 3 d after discontinuation 
of tamoxifen, splenocytes from treated mice were harvested, and B cells were 
negatively selected using CD43-MACS beads (Miltenyi Biotec). After puri-
fi  cation, cells were stained with Cy5-conjugated anti-IgM Fab fragments, 
washed twice, and labeled with Fluo-3 and Fura Red (Invitrogen). Ca2+ fl  ux 
of B cells resuspended at 2 × 106 cells/ml in Krebs-Ringer solution (1 mM 
Ca2+) was assayed by fl  ow cytometry (FACSCalibur), measuring the fl  uores-
cence emission of Fluo-3 in the FL-1 channel and Fura Red in the FL-3 
channel. Data were analyzed using FlowJo software.
Immunohistochemistry. For histological staining of B cells and T cells, 
frozen 6-μm sections were thawed, air dried, fi  xed in acetone, and stained 
for 1 h at room temperature in a humidifi  ed chamber with rat anti-CD19 
(ID3; BD Biosciences) and biotinylated anti-CD3 (145-2C11; BD Bio-
sciences), followed by HRP-conjugated goat anti–rat IgG and alkaline phos-
phatase–conjugated streptavidin (Southern Biotechnology Associates, Inc.).
Online supplemental material. Fig. S1 shows the targeting strategy to 
generate IgHγ1μ or IgHμγ1 alleles. Fig. S2 and Fig. S3 demonstrate enhanced 
Ca2+ responses in lymph-node B cells of IgHγ1μ/γ1μ mice or acutely switched 
splenic B cells, respectively. Fig. S4 shows that CD22 defi  ciency does not aff  ect 
B cell development in IgHγ1μ/ γ1μ mice but results in accumulation of a higher 
number of IgG1+ cells in heterozygous mice. Fig. S5 demonstrates that IgG1+ 
B cells do not develop in the absence of Igα. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20062024/DC1.
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